Benjamin T. Dake, SEE REMARKS at Aerovate Therapeutics, Inc. (AVTE), sold 20,566 shares at $16.11 ($331K) on 2023-12-06, disclosed to the SEC on 2023-12-07.
Scheduled sale ($331k) by SEE REMARKS under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $16.11 | 10,283 | $166K | 50.0% |
| 2 | $16.11 | 10,283 | $166K | 50.0% |
| Total | $16.11 avg | 20,566 | $331K | 100% |
| Filing → |
| AVTE | SELL | 2024-03-28 | $619K | — | Filing → |
| AVTE | SELL | 2024-03-27 | $192K | — | Filing → |
| AVTE | SELL | 2024-03-20 | $1.8M | — | Filing → |